Cell Mogrify gets £420k funding for regenerative cell therapiesUK cell therapy company Cell Mogrify has been awarded £420,000 funding from Innovate UK to accelerate its data-driven Share XCell Mogrify gets £420k funding for regenerative cell therapieshttps://pharmaphorum.com/news/cell-mogrify-gets-420k-funding-for-regenerative-cell-therapies/
Will cell and gene therapies disrupt reimbursement?Cell and gene therapies could prove disruptive in terms of the life-changing benefits they could bring to people Share XWill cell and gene therapies disrupt reimbursement?https://deep-dive.pharmaphorum.com/magazine/disruptive-technologies/will-cell-and-gene-therapies-disrupt-drug-reimbursement/
Nearly 300 gene and cell therapies in development – reportPharma is becoming increasingly focused on gene and cell therapies, with nearly 300 in clinical development or awaiting Share XNearly 300 gene and cell therapies in development – reporthttps://pharmaphorum.com/news/nearly-300-gene-and-cell-therapies-in-development-report/
Roche and SQZ expand cell therapy deal to more than $1.3bnUS biotech SQZ Biotechnologies has expanded a collaboration with Roche to develop cancer therapies based on antigen presenting Share XRoche and SQZ expand cell therapy deal to more than $1.3bnhttps://pharmaphorum.com/news/roche-and-sqz-expand-cell-therapy-deal-to-more-than-1-3bn/
Gilead signs biotech deal arming T-cells to attack solid tumoursGilead’s Kite unit has signed a deal with the biotech HiFiBiO (High Fidelity Biology) to discover T-cell receptors Share XGilead signs biotech deal arming T-cells to attack solid tumourshttps://pharmaphorum.com/news/gilead-signs-biotech-deal-arming-t-cells-to-attack-solid-tumours/
From Manufacturing to Patient Access: SMi’s Cell & Gene Therapy 2018Cell & Gene Therapy Share XFrom Manufacturing to Patient Access: SMi’s Cell & Gene Therapy 2018https://pharmaphorum.com/partner-content/from-manufacturing-to-patient-access-smis-cell-gene-therapy-2018/
Explore the latest developments in ATMPs at Cell & Gene Therapy 2018Cell and Gene Therapy 2018 Share XExplore the latest developments in ATMPs at Cell & Gene Therapy 2018https://pharmaphorum.com/partner-content/explore-the-latest-developments-in-atmps-at-cell-gene-therapy-2018-2/
Kite expands manufacturing capacity for CAR-T therapiesLess than a year after it was acquired by Gilead in a $11.9 billion deal, Kite Pharma has Share XKite expands manufacturing capacity for CAR-T therapieshttps://pharmaphorum.com/news/kite-expands-manufacturing-capacity-for-car-t-therapies/
Cell & Gene Therapy 2018Cell & Gene Therapy Share XCell & Gene Therapy 2018https://pharmaphorum.com/events/cell-gene-therapy-2018/